News and features

The ICR, specialist cancer drug discovery business Sareum and Cancer Research Technology Limited are pleased to announce the selection of a preclinical development candidate from their joint research collaboration.

Scientists at the ICR and The Royal Marsden have developed an advanced type of MRI scan that can detect whether late-stage ovarian cancers are responding to chemotherapy treatment after just one cycle, which should help doctors decide whether to continue or alter treatment.

ICR scientists have made the most significant ovarian cancer gene discovery for more than a decade, finding women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing the disease.

Pioneering scientists at the ICR's Breakthrough Breast Cancer Research Centre have created the world’s first encyclopaedia of genes that drive breast cancer. It is hoped that new targeted treatments leading directly from this work will be in clinical trials in the next few years.

ICR scientists have conducted the first whole-genome scan of the brain tumour meningioma and revealed a genetic region that increases the risk of developing the disease.

Professor Chris Marshall has been named as the recipient of this year’s Cancer Research UK Lifetime Achievement Prize.

The ICR and The Royal Marsden welcome the European pharmaceutical regulator’s recommendation that abiraterone acetate, trade name Zytiga™, be approved for use in men with metastatic castration-resistant prostate cancer.

Cancer Research UK has awarded Dr Claus Jorgensen from the ICR a prestigious award as part of a series of grants given to new investigators who are set to become the eminent cancer scientists of the future.

The ICR is leading a project to create the most comprehensive genetic map of prostate cancer yet assembled, which will transform our understanding of the disease and pave the way to better and more targeted treatments. A second project aims to identify genetic faults driving oesophageal cancer.

Scientists from leading London research centres met this week to discuss new ways to help cancer patients by combining their strengths in physics, clinical activities and basic research.

Researchers at the ICR and University of Cambridge led an international study that discovered seven new variants in the human genome that increase the chances of developing prostate cancer.

Scientists have uncovered a new way of killing cancer cells, opening up a potentially highly effective avenue of attack in the fight against all forms of the disease.